Evidence map›Paper›PMID 27624133›Full record

ArticlemBio2016

Global Identification of Biofilm-Specific Proteolysis in Candida albicans.

Michael B Winter, Eugenia C Salcedo, Matthew B Lohse, Nairi Hartooni, Megha Gulati, Hiram Sanchez, Julie Takagi, Bernhard Hube, David R Andes, Alexander D Johnson and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Understanding the Effect of Propolis and Its Derivatives AgainstJournal of fungi (Basel, Switzerland) · 2026
    Review
  4. Review
  5. UnderstandingJournal of medical microbiology · 2026
    Review
  6. Article
  7. Article
  8. Secretion of serine proteases by planktonic- and biofilm-growing cells of Candida parapsilosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  9. Review
  10. Article
  11. Microbiology and molecular biology reviews : MMBR · 2024
    Review
  12. Secreted Aspartic Proteinases: Key Factors inInternational journal of molecular sciences · 2024
    Review
  13. Biofilm Formation in Medically ImportantJournal of fungi (Basel, Switzerland) · 2023
    Review
  14. Review
  15. Article
  16. Frontiers in cellular and infection microbiology · 2023
    Article
  17. The human pathobiontProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  18. The Role ofPathogens (Basel, Switzerland) · 2022
    Article
  19. Article
  20. Biofilm Alterations on the Stepwise Acquisition of Fluconazole-resistantInternational journal of dermatology and venereology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Michael B WinterDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, USA.
Eugenia C SalcedoChemistry and Chemical Biology Graduate Program, University of California, San Francisco, California, USA.
Matthew B LohseDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA Biosynesis, Inc., San Francisco, California, USA.
Nairi HartooniTetrad Graduate Program, University of California, San Francisco, California, USA.
Megha GulatiDepartment of Molecular and Cell Biology, University of California, Merced, California, USA.
Hiram SanchezDepartment of Medicine, University of Wisconsin, Madison, Wisconsin, USA Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Madison, Wisconsin, USA.
Julie TakagiDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Bernhard HubeDepartment of Microbial Pathogenicity Mechanisms, Hans Knoell Institute, Jena, Germany.
David R AndesDepartment of Medicine, University of Wisconsin, Madison, Wisconsin, USA Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Madison, Wisconsin, USA.
Alexander D JohnsonDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA cnobile@ucmerced.edu Charles.Craik@ucsf.edu ajohnson@cgl.ucsf.edu.
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, California, USA cnobile@ucmerced.edu Charles.Craik@ucsf.edu ajohnson@cgl.ucsf.edu.
Clarissa J NobileDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA Department of Molecular and Cell Biology, University of California, Merced, California, USA cnobile@ucmerced.edu Charles.Craik@ucsf.edu ajohnson@cgl.ucsf.edu.
University of California, San Francisco · USUniversity of Wisconsin–Madison · USLeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DEUniversity of California, Merced · US

Funding

Maximizing Opportunities for Research Excellence - Evaluation Training SupplementR25GM056847 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUNCAN, D'ANNE S., SELLO, JASON K · 1998 to 2023
$14.1M
TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1M
Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
Vesicle-mediated drug resistance of Candida albicans biofilmR01AI073289 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, MITCHELL, AARON P · 2008 to 2025
$7.9M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
The transcriptional circuitry controlling biofilm development in Candida albicansR01AI083311 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSON, ALEXANDER D · 2011 to 2020
$4.3M
Allosteric Inhibition of a Family of Proteolytic EnzymesR01GM104659 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2013 to 2016
$1.2M
Genetic Analysis of the Transcriptional Network Governing C. albicans BiofilmsR00AI100896 · NIAID · UNIVERSITY OF CALIFORNIA, MERCED · PI NOBILE, CLARISSA JANE · 2014 to 2015
$498k
Profiling the Role of Protease Activity in Cancer ProgressionF32CA168150 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WINTER, MICHAEL B. · 2012 to 2014
$136k
NCI NIH HHS F32 CA168150NCI NIH HHS T32 CA108462NIAID NIH HHS R00 AI100896NIAID NIH HHS R01 AI073289NIAID NIH HHS R01 AI083311NIAID NIH HHS T32 AI060537NIEHS NIH HHS T32 ES007020NIGMS NIH HHS P41 GM103481NIGMS NIH HHS R01 GM104659NIGMS NIH HHS R25 GM056847NIGMS NIH HHS T32 GM064337
6 · The paper itself

Abstract

unlabelledCandida albicans is a fungal species that is part of the normal human microbiota and also an opportunistic pathogen capable of causing mucosal and systemic infections. C. albicans cells proliferate in a planktonic (suspension) state, but they also form biofilms, organized and tightly packed communities of cells attached to a solid surface. Biofilms colonize many niches of the human body and persist on implanted medical devices, where they are a major source of new C. albicans infections. Here, we used an unbiased and global substrate-profiling approach to discover proteolytic activities produced specifically by C. albicans biofilms, compared to planktonic cells, with the goal of identifying potential biofilm-specific diagnostic markers and targets for therapeutic intervention. This activity-based profiling approach, coupled with proteomics, identified Sap5 (Candidapepsin-5) and Sap6 (Candidapepsin-6) as major biofilm-specific proteases secreted by C. albicans Fluorogenic peptide substrates with selectivity for Sap5 or Sap6 confirmed that their activities are highly upregulated in C. albicans biofilms; we also show that these activities are upregulated in other Candida clade pathogens. Deletion of the SAP5 and SAP6 genes in C. albicans compromised biofilm development in vitro in standard biofilm assays and in vivo in a rat central venous catheter biofilm model. This work establishes secreted proteolysis as a promising enzymatic marker and potential therapeutic target for Candida biofilm formation. IMPORTANCE: Biofilm formation by the opportunistic fungal pathogen C. albicans is a major cause of life-threatening infections. This work provides a global characterization of secreted proteolytic activity produced specifically by C. albicans biofilms. We identify activity from the proteases Sap5 and Sap6 as highly upregulated during C. albicans biofilm formation and develop Sap-cleavable fluorogenic substrates that enable the detection of biofilms from C. albicans and also from additional pathogenic Candida species. Furthermore, SAP5 and SAP6 deletions confirm that both proteases are required for proper biofilm development in vitro and in vivo We propose that secreted proteolysis is a promising marker for the diagnosis and potential therapeutic targeting of Candida biofilm-associated infections.

Indexed as

ProteolysisAnimalsAspartic Acid EndopeptidasesBiofilmsCandida albicansCandidiasisCatheter-Related InfectionsDisease Models, AnimalFungal ProteinsProteomeRatsAspartic Acid EndopeptidasesFungal ProteinsProteomeSAP5 protein, Candida albicansSAP6 protein, Candida albicans

Identifiers

PMID27624133
PMCPMC5021810
OpenAlexW2518966090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.